Literature DB >> 1717366

Murine monoclonal anti-Ba antibody that enhances haemolytic activity of factor B.

E Tanaka1, K Hong, T Kinoshita, Y Takata, H Kozono, J Takeda, A Yoden, K Inoue.   

Abstract

A murine monoclonal antibody (mAb 20-ET) (IgG1, kappa) was selected from a panel of stable hybridomas produced by fusion of P3-X-63-Ag8-U1 (P3UI) myeloma cells with spleen cells from a BALB/c mouse immunized with human factor B. This antibody was shown by the immune blotting method to be directed against the Ba domain of factor B. The haemolytic activity of factor B was enhanced dose-dependently by mAb 20-ET when it was incubated with factor B and EAC4b, 3b cells (sensitized erythrocytes bearing complement fragments C4b and C3b). However, when the antibody was added after factor B had been bound to EAC4b,3b cells and the cells had been washed, it caused little enhancement of the haemolytic activity. The enhancing effect of this antibody was not due to its stabilization of the C3b-B complex, because EAC4b,3b dissociated from mAb 20-ET-bound factor B complexes rather more readily than from uncomplexed factor B. The presence of mAb 20-ET in the reaction mixture caused and maintained a much higher steady-state level of binding of factor B with EAC4b,3b cells than that in its absence. Factor P caused delayed dissociation of mAb-bound factor B from EAC4b,3b cells, thus enhancing the haemolytic activity of factor B bound with the mAb.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717366      PMCID: PMC1384564     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  20 in total

1.  Probing functional sites on complement protein B with monoclonal antibodies. Evidence for C3b-binding sites on Ba.

Authors:  A Ueda; J F Kearney; K H Roux; J E Volanakis
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

2.  Surface-specific iodination of membrane proteins of viruses and eucaryotic cells using 1,3,4,6-tetrachloro-3alpha,6alpha-diphenylglycoluril.

Authors:  M A Markwell; C F Fox
Journal:  Biochemistry       Date:  1978-10-31       Impact factor: 3.162

3.  The purification and properties of the second component of human complement.

Authors:  M A Kerr; R R Porter
Journal:  Biochem J       Date:  1978-04-01       Impact factor: 3.857

4.  The isolation and characterization of a new component of hemolytic complement, C'3e.

Authors:  K Inoue; R A Nelson
Journal:  J Immunol       Date:  1965-08       Impact factor: 5.422

5.  Effect of trypsinization on the activity of human factor H.

Authors:  K Hong; T Kinoshita; Y Dohi; K Inoue
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

6.  Native and activated properdin: interconvertibility and identity of amino- and carboxy-terminal sequences.

Authors:  R G Medicus; A F Esser; H N Fernandez; H J Müller-Eberhard
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

7.  The alternative pathway C3/C5 convertase: chemical basis of factor B activation.

Authors:  P H Lesavre; T E Hugli; A F Esser; H J Müller-Eberhard
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

8.  Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.

Authors:  M R Daha; A M Deelder; L A Van Es
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

9.  Large scale isolation of functionally active components of the human complement system.

Authors:  C H Hammer; G H Wirtz; L Renfer; H D Gresham; B F Tack
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

10.  Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.

Authors:  E L Pryzdial; D E Isenman
Journal:  J Biol Chem       Date:  1987-02-05       Impact factor: 5.157

View more
  2 in total

1.  Binding ability of complement receptor CR1 to C3 bound on the surface of M+ group A streptococci.

Authors:  K Hong; T Harada; T Nishimura; K Inoue
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

2.  Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B.

Authors:  C W Clardy
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.